BAMPSL Sec. (531591)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades below book value at ₹8.80 versus ₹11.13, providing a tangible asset cushion on paper.
• Latest quarter is profitable with ₹7 Cr sales and ₹1 Cr net profit.
• Annual sales show modest growth of 3.30%.
• Small market cap of ₹30 Cr could offer upside if a genuine turnaround or re-rating occurs.

Concerns

• Profit growth is sharply negative at -37.50% while P/E is high at 34.07, indicating expensive earnings.
• ROE of 5.17% and ROCE of 4.69% are too low to create meaningful shareholder value.
• Piotroski F-Score of 4/9 suggests weak financial health.
• Current price below the stated 52-week range raises serious questions about data reliability or underlying deterioration.

AI Analysis

At ₹8.80, this small NBFC is selling at a meaningful discount to its book value of ₹11.13, a 0.79 P/B. Benjamin Graham taught me to respect a margin of safety, and on paper this looks like an asset play. But Graham also insisted that a discount to book is only attractive if management can earn a reasonable return on those assets. Here, ROE is just 5.17% and ROCE is 4.69%, both barely better than a fixed deposit. The earnings power is weak. Profit growth has collapsed by 37.50%, and the P/E stands at 34.07. As earnings fall, the stock still carries a rich earnings multiple, which is dangerous. The Piotroski F-Score of 4/9 reinforces my caution: the financial health is mediocre at best. Sales growth is only 3.30%, hardly a sign of an expanding franchise. The latest quarter shows sales of ₹7 Cr and net profit of ₹1 Cr, so the business is not dead, but I see no durable moat, no pricing power, and no clear competitive advantage. The dividend yield is zero, so I am not being paid to wait. The promoter holding is not disclosed, which troubles me; a small NBFC should be transparent. Interestingly, the current price is below the stated 52-week range of ₹15.20 to ₹25.49. That discrepancy is alarming and may indicate stale data or a sharp deterioration in the underlying asset quality. As an investor, I prefer a wonderful business at a fair price over a mediocre business at a low price. This appears to be a cheap asset that may stay cheap. I would demand deep evidence of asset quality, capital allocation, and a clear path to improving returns before would consider buying, regardless of the low P/B.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer